A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

BACKGROUND: Eribulin mesylate is a synthetic microtubule inhibitor that showed cytotoxic synergy in combination with gemcitabine preclinically. This combination was assessed in a Phase I dose-finding trial in patients diagnosed with advanced solid tumours who had received up to two prior chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Lheureux, S, Oza, A M, Laurie, S A, Halford, R, Jonker, D, Chen, E, Keller, D, Bourade, V, Wang, L, Doyle, L, Siu, L L, Goel, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705880/
https://www.ncbi.nlm.nih.gov/pubmed/26554651
http://dx.doi.org/10.1038/bjc.2015.343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705880/
https://www.ncbi.nlm.nih.gov/pubmed/26554651
http://dx.doi.org/10.1038/bjc.2015.343

Ejemplares similares